Dr. Reddy’s (NYSE: RDY) details Delhi court ruling on Semaglutide exports

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories responded to media reports about a Delhi High Court decision involving Semaglutide products and a dispute with Novo Nordisk. The company explains that the court’s Division Bench upheld an earlier order allowing it to manufacture Semaglutide in India and export it to countries where Novo Nordisk does not hold a patent registration, while refusing an interim injunction on Semaglutide products. Dr. Reddy’s emphasizes that the litigation remains sub judice and that, in its view, there is currently no material event or information requiring disclosure under Regulation 30 of the SEBI Listing Regulations.

Insights

Pharmaceutical legal and regulatory analyst

Dr. Reddy’s clarifies a Semaglutide patent dispute outcome without calling it a material event.

The company describes an ongoing interim injunction proceeding with Novo Nordisk over Semaglutide products. A Delhi High Court Division Bench upheld an earlier order permitting Dr. Reddy’s to manufacture Semaglutide in India and export it to jurisdictions where Novo Nordisk lacks patent protection, while refusing an interim injunction.

Because the case remains sub judice, Dr. Reddy’s frames this as a procedural stage in a broader patent dispute rather than a final resolution. It explicitly states there is no event at this stage that it believes requires disclosure under Regulation 30 of the SEBI Listing Regulations, indicating a conservative stance on materiality and disclosure obligations.

Future court developments in this matter could alter the company’s rights around Semaglutide manufacturing and exports. Investors can look to subsequent official communications and statutory disclosures from Dr. Reddy’s for any change in the legal position or recognition of a material event arising from this litigation.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

March, 2026

Commission File Number 1-15182

  ​

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                                No   x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated March 10, 2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: March 10, 2026	By:	/s/ K Randhir Singh
		Name: K Randhir Singh
		Title:   Company Secretary

3

Exhibit 99.1

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel:       + 91 40 4900 2900 Fax:     + 91 40 4900 2999 Email: mail@drreddys.com Web:   www.drreddys.com

March 10, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – News article with the heading “Delhi High Court allows Dr Reddy's to make Semaglutide for export”

This is in reference to a news article published on March 10, 2026, including the article in Business Standard titled “Delhi High Court allows Dr Reddy's to make Semaglutide for export” (https://www.business-standard.com/india-news/delhi-hc-allows-dr-reddys-to-manufacture-semaglutide-for-export-126030900996_1.html). Similar reports have also appeared in other mainstream media..

In this regard, the Company hereby clarify that the said news pertains to an ongoing interim injunction proceeding between the Company and Novo Nordisk, a Danish drug maker, involving Semaglutide containing products. The Division Bench of Delhi High Court, through its judgment dated March 09, 2026, has upheld the previous Single-Judge Bench’s order that permitted the Company to manufacture Semaglutide in India and export to other countries where Novo Nordisk does not hold a patent registration, refusing to grant an interim injunction on Semaglutide containing products.

We would further like to inform that the matter remains sub-judice and at this stage there is no material event/ information that requires disclosure under Regulation 30 of the SEBI Listing Regulations.

This is for your information and records.

Thanking you,

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer and Head-CSR

FAQ

What legal issue involving Semaglutide does Dr. Reddy’s (RDY) describe in this filing?

Dr. Reddy’s describes an interim injunction proceeding with Novo Nordisk over Semaglutide products. The dispute concerns the company’s ability to manufacture Semaglutide in India and export to countries where Novo Nordisk does not have patent registration.

What did the Delhi High Court decide regarding Dr. Reddy’s Semaglutide exports?

The Delhi High Court’s Division Bench upheld an earlier Single-Judge order. That order permits Dr. Reddy’s to manufacture Semaglutide in India and export it to countries where Novo Nordisk does not hold a patent, while refusing an interim injunction on Semaglutide products.

How does Dr. Reddy’s (RDY) respond to media reports about the Semaglutide case?

Dr. Reddy’s states that recent media articles, including one in Business Standard, relate to an ongoing court proceeding with Novo Nordisk. It clarifies the exact scope of the Delhi High Court decision and reiterates that the matter remains before the court.

Does Dr. Reddy’s consider the Semaglutide court ruling a material event?

Dr. Reddy’s explicitly states that, at this stage, there is no material event or information arising from the Semaglutide proceedings that requires disclosure under Regulation 30 of the SEBI Listing Regulations, reflecting its assessment of current materiality.

What is the current status of the Semaglutide litigation involving Dr. Reddy’s and Novo Nordisk?

The company notes that the Semaglutide-related matter remains sub judice. Although the Delhi High Court Division Bench upheld the earlier order and refused an interim injunction, the broader dispute between Dr. Reddy’s and Novo Nordisk continues before the court.

Which exchanges did Dr. Reddy’s (RDY) inform about the Semaglutide clarification?

Dr. Reddy’s sent its clarification to the National Stock Exchange of India, BSE Limited, the New York Stock Exchange, and NSE IFSC. The letter ensures that investors across these markets receive consistent information on the Semaglutide court development.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 RDY0857_EX99-1 27.5 KB